Hosted on MSN6d
GSK’s Nucala approved in China as add-on therapy for adults with CRSwNP
GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that ...
Hosted on MSN3d
China’s NMPA approves GSK’s Nucala for CRSwNP treatment
The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with ...
GSK's Sinus Disease Drug Secures Approval In China
On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on ...
GSK’s Nucala Gains Approval in China for CRSwNP
GlaxoSmithKline ( (GSK) ) has provided an update. GSK announced that its monoclonal antibody, Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with ...
GSK's Nucala gets third approval in China
GSK announced on Friday that its monoclonal antibody ‘Nucala’, or mepolizumab, has received approval from China's National ...
The Pharma Letter6d
GSK’s Nucala wins wider approval in China
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...
Business Insider1mon
GSK: FDA Accepts For Review Submission For New Indication Of Nucala In COPD
Mepolizumab is a monoclonal antibody that targets ... 390 million people globally and over 14 million people in the US. GSK noted that recurrent exacerbations add to pressures on healthcare ...
Daily5d
GSK Nucala approved in China for treatment of adults with chronic rhinosinusitis with nasal polyps
London: GSK plc has announced that the China National Medical Products Administration has approved Nucala (mepolizumab), a ...
pharmaphorum3d
GSK says Nucala hits the target in new COPD trial
GSK's severe asthma therapy Nucala could find ... The headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically significant reduction ...
Pharmabiz6d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps: London, UK Saturday, January 4, 2025, 09:00 Hrs [IST] GSK plc announced ...
Business Insider1mon
GSK announces U.S. FDA accepted its submission for use of Nucala in COPD
GSK (GSK) announced the US Food and Drug Administration ... which evaluated the efficacy and safety of mepolizumab in 804 patients with COPD who have evidence of type 2 inflammation characterised ...
GSK treatment approved for adults with sinus condition in China
(Alliance News) - GSK PLC on Friday reported that its Nucala treatment has been approved in China to treat long-term sufferers of a sinus ailment following a phase 3 study.